A5090712551- Pancreatic and Hepatic Oncology Research
- Organ Transplantation Techniques and Outcomes
- Intraperitoneal and Appendiceal Malignancies
- Appendicitis Diagnosis and Management
- Bariatric Surgery and Outcomes
- Pancreatitis Pathology and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Colorectal Cancer Surgical Treatments
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Esophageal and GI Pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Renal Transplantation Outcomes and Treatments
- Cancer Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Ovarian cancer diagnosis and treatment
- Hernia repair and management
- Liver Disease Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Blood transfusion and management
- Organ Donation and Transplantation
- Gastrointestinal disorders and treatments
North Shore Diabetes and Endocrine Associates
2025
Lenox Hill Hospital
2025
Cornell University
2022-2023
NewYork–Presbyterian Hospital
2022-2023
New York Hospital Queens
2022-2023
Presbyterian Hospital
2022-2023
Weill Cornell Medicine
2022-2023
University of Cincinnati Medical Center
2016-2022
University of Cincinnati
2016-2020
Oncology Hematology Care
2018
Morbid obesity is a barrier to kidney transplantation due inferior outcomes, including higher rates of new-onset diabetes after (NODAT), delayed graft function (DGF), and failure. Laparoscopic sleeve gastrectomy (LSG) increases transplant eligibility by reducing BMI in candidates, but the effect surgical weight loss on posttransplantation outcomes unknown. Reviewing single-center medical records, we identified all patients who underwent LSG before from 2011-2016 (n = 20). Post-LSG recipients...
In patients with borderline resectable pancreas cancers, clinicians frequently consider radiographic response as the primary driver of whether should be offered surgical intervention following neoadjuvant therapy (NT). We sought to determine any correlation between and pathologic rates NT.Between 2005 2015, 38 at a tertiary care referral center underwent NT followed by pancreaticoduodenectomy for cancer. Radiographic after completion surgery were graded according RECIST Evans' criteria,...
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated improved survival for patients colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant (NAC) prior to CRS-HIPEC poorly understood. A retrospective review adult CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) first (SF). Patients had lower cancer index score (12.1 + 7.9 vs. 14.3 8.5, p =...
The relevance of margin positivity on recurrence after resection intraductal papillary mucinous neoplasms (IPMNs) is poorly defined and represents one reason controversy remains regarding optimal surveillance recommendations.Patients undergoing surgery for noninvasive IPMN at 8 academic medical centers from the Central Pancreas Consortium were analyzed. A positive was as presence or pancreatic intraepithelial neoplasia.Five hundred two patients underwent IPMN; 330 (66%) did not have invasive...